GLP-1 Therapy and Exercise for Obesity
This study is looking at how a medication called semaglutide (a GLP-1 receptor agonist) combined with exercise training affects people with obesity. Researchers want to see how this combination impacts your physical function (how well you can do daily activities) and body composition (the amount of fat and muscle in your body). They are also studying what happens to these measures a year after stopping the treatment. You might be able to join if you are 50 to 75 years old, have obesity (BMI of 30 or higher), and have decreased physical function. The study plans to enroll 40 participants, but its current status is unclear.
- Study design
- This is an interventional study planning to enroll 40 participants. It will compare semaglutide and exercise training.
- What's involved
- Participants will perform supervised exercise 3 days a week and unsupervised exercise 2-3 days a week. They will also receive semaglutide injections weekly and diet counseling for one year.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your physical function and body composition will be measured at the start, after 52 weeks of treatment, and 52 weeks after stopping the treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07091500
Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity
Recruiting
NAAges 50–75InterventionalBasic scienceWashington University School of MedicineInvestigator-initiated
~40 participants
Updated 2026-07-10 on ClinicalTrials.gov
What's tested:Exercise trainingSemaglutideTherapy Cessation
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Physical function
Measured over Baseline, after 52 weeks of intervention, and 52 weeks after stopping the intervention
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMissouri1
Study leadership
- Joseph W Beals, PhD · STUDY_DIRECTOR · Washington University School of Medicine
- Samuel Klein, MD · PRINCIPAL_INVESTIGATOR · Washington University School of Medicine
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
i) obesity (Body Mass Index ≥ 30 kg/m2)
ii) decreased physical function (Modified Physical Performance Test score 17 to 31)
iii) approval of their primary physician to participate in this study.
Exclusion
i) unstable weight (\>4% change during the last 2 months before entering the study)
ii) ≥150 min per week of structured exercise (e.g., jogging, activities that cause heavy breathing and sweating)
iii) diabetes
iv) significant cardiopulmonary disease (heart failure, angina, uncontrolled hypertension, chronic obstructive pulmonary disease) or other organ dysfunction (e.g., renal insufficiency \[eGFR \<30 mL/min/1.73 m2\])
v) therapy with a GLP-1 or other weight loss medications
vi) clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal motility
vii) history of chronic or acute pancreatitis
viii) thyroid-stimulating hormone (TSH) \>1.5X the upper limit of normal (patients receiving treatment for hypothyroidism may be included provided their thyroid hormone replacement dose has been stable for at least 3 months)
ix) history of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 months that would interfere with study participation
x) acute or chronic hepatitis, or other liver disease other than Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)
xi) family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
xii) history of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years
xiii) tobacco use, excessive alcohol intake (≥3 drinks/day for men and ≥2 drinks/day for women) or active substance abuse with illegal drugs by self-report, or regular marijuana use within 3 months of enrollment and unwilling to abstain from marijuana during the trial
xiv) Use of medications that are known to affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued for this study
xv) have had bariatric surgery or plan to have endoscopic or bariatric surgery therapy for obesity
xvi) anemia (Hgb \<10 g/dL)
xvii) Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)
xii) history of seizure disorder
xix) Female who is pregnant, breast-feeding or intends to become pregnant
xx) allergy or hypersensitivity to GLP-1 RA medications
xxi) unable to grant voluntary informed consent
xxii) unable or unwilling to follow the study protocol or who, for any reason, the research team considers the participant is not an appropriate candidate for the study
What this trial measures
- Physical functionBaseline, after 52 weeks of intervention, and 52 weeks after stopping the intervention
Score on the Modified Physical Performance Test
- Body compositionBaseline, after 52 weeks of intervention, and 52 weeks after stopping the intervention
DEXA scan